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Abstract O-linked L-N-acetylglucosamine (O-GlcNAc) is a
dynamic nucleocytoplasmic post-translational modi¢cation
more analogous to phosphorylation than to classical complex
O-glycosylation. A large number of nuclear and cytosolic
proteins are modi¢ed by O-GlcNAc. Proteins modi¢ed by
O-GlcNAc include transcription factors, signaling components,
and metabolic enzymes. While the modi¢cation has been known
for almost 20 years, functions for the monosaccharide modi¢-
cation are just now emerging. In this review, we will focus on the
cycling enzymes and emerging roles for this post-translational
modi¢cation in regulating signal transduction and transcription.
Finally, we will discuss future directions and the working model
of O-GlcNAc serving as a nutrient sensor.
* 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
O-linked L-N-acetylglucosamine (O-GlcNAc), which was
described in 1984, is a monosaccharide modi¢cation abundant
on serine and threonine residues of a multitude of nucleocy-
toplasmic proteins [1]. Over the intervening years, the number
of modi¢ed nuclear and cytoplasmic proteins identi¢ed has
reached nearly 100 and includes transcription factors, cyto-
skeletal components, metabolic enzymes, and signaling com-
ponents (reviewed in [2,3]). The enzymes responsible for
O-GlcNAc addition (O-GlcNAc transferase, OGT) and re-
moval (neutral L-N-acetylglucosaminidase, O-GlcNAcase)
have been cloned and partially characterized in the last 6
and 2 years, respectively (reviewed in [4]). Work showing
the dynamic and inducible nature of the modi¢cation has
suggested that O-GlcNAc is a regulatory modi¢cation, but
only work in the last few years has begun to elucidate
O-GlcNAc’s biological roles [5,6]. Thus, the ‘O-GlcNAc ¢eld’
is still relatively immature compared to the much better
understood phosphorylation ¢eld. It is attractive to compare
O-GlcNAc to serine/threonine phosphorylation as they share
several key features including the residues and proteins they
modify, their dynamic and inducible nature, and the existence
of cycling enzymes [7].
In 1992, Edwin G. Krebs described the lengthy time that it
took for phosphorylation/dephosphorylation to be accepted
as a mechanism for regulating proteins, especially outside
the glycogen metabolism ¢eld [8]. In particular, Krebs and
Fischer’s groundbreaking work in the mid to late 1950s
came 25 years after the discovery of serine/threonine phos-
phorylation in 1933. After the pioneering phosphorylase ki-
nase work by Krebs and Fischer, it would take another de-
cade before it was recognized that phosphorylation could be
regulated by extracellular stimuli (cAMP and protein kinase
A, 1968, [9,10]) and another decade after that (1976) before
the number of enzymes known to undergo phosphorylation/
dephosphorylation exceeded 20 [8]. O-GlcNAc will soon be
celebrating its 20th anniversary and likewise only recent
work has begun to shed light on the biological function of
this abundant modi¢cation [11,12]. A signi¢cant portion of
the time and e¡ort in the last 20 years in this small but grow-
ing ¢eld has focused on generating the necessary methods and
tools to study this monosaccharide (reviewed in [13]). In this
review, we will brie£y discuss the cycling enzymes (reviewed in
[4]) and then focus on the accumulating data that O-GlcNAc
is involved in regulating protein function. We will conclude by
describing the working model that O-GlcNAc is serving as a
nutrient-sensor master switch that attenuates cellular re-
sponses to extracellular stimuli.
2. The cycling enzymes for O-GlcNAc modi¢cation of
nucleocytoplasmic proteins (see Fig. 1)
OGT (uridine diphospho-N-acetylglucosamine:polypeptide
L-N-acetylglucosaminyltransferase, EC 2.4.1) was originally
puri¢ed to near homogeneity in 1992 from rat liver [14]. At
that time, it was determined that it had a native molecular
weight of approximately 340 kDa [14]. The rat, human, and
Caenorhabditis elegans genes were cloned almost simulta-
neously in 1997 [15,16]. Following ¢ne mapping of the human
OGT gene to generate a full-length sequence [17], it was found
that the human and rat sequence are nearly 100% homolo-
gous. Attempted knock-out studies in mice showed that the
gene for OGT resides on the X chromosome and is necessary
for embryonic stem cell viability [18]. In most tissues, the
protein is a trimer composed of three 110 kDa polypeptides
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and each polypeptide appears to be composed of two do-
mains. The N-terminus of the mammalian polypeptide con-
tains 11.5 tetratricopeptide repeats. These repeats are thought
to be involved in mediating protein^protein interactions [19]
and it has been shown that these repeats in OGT impact on
protein trimerization and substrate recognition [20^22]. The
C-terminus of the protein appears to be the catalytic domain
of the protein with a putative UDP-GlcNAc binding site and
weak homology to the glycogen phosphorylase/glycosyl trans-
ferase family [23]. Furthermore, a 100 amino acid deletion
from the C-terminus results in a catalytic inactive enzyme
[21,24]. Recent work has identi¢ed proteins that interact
with OGT and these proteins may be targeting OGT to sub-
cellular locations (Fig. 1, [22,24]). Also, Hanover and col-
leagues have recently shown that there are multiple isoforms
of OGT and at least one splice variant is targeted to the
mitochondria [25,26]. OGT has also been shown to be
O-GlcNAc-modi¢ed itself as well as tyrosine-phosphorylated
[15]. Understanding the regulation of this enzyme will be key
to future investigations of the O-GlcNAc modi¢cation.
The existence of a neutral L-N-acetylglucosaminidase
(termed hexC) has been known for over 25 years [27]. Dong
et al. partially puri¢ed and characterized this nucleocytoplas-
mic enzyme and termed it O-GlcNAcase in 1994 [28]. Cloning
and characterization of the enzyme in the last couple of years
[29,30] suggest that O-GlcNAcase most likely represents the
previously described hexC activity. The primary sequence of
O-GlcNAcase had previously been identi¢ed as a meningio-
ma-expressed antigen and showed weak hyaluronidase activity
[31]. Furthermore, while the putative hyaluronidases and
O-GlcNAcase activity are in the N-terminus, the C-terminus
shows weak homology to histone acetyltransferases in the
C-terminus [32]. The possibility that this one polypeptide
has multiple enzymatic activities is currently being explored.
The 916 amino acid enzyme is quite distinct from the lyso-
somal hexosaminidases [29,30]. Most notable is O-GlcNAc-
ase’s localization primarily to the cytosol and to a lesser
extent the nucleus. O-GlcNAcase is also not a general
hexosaminidase but instead is a speci¢c L-N-acetylglucosami-
nidase, and thus it is not inhibited by N-acetylgalactosamine.
Compared to OGT and due to its recent cloning, little infor-
mation is currently known about interacting proteins, post-
translational modi¢cation, and regulation of the enzyme. It is
interesting to note that while the recombinant enzyme mi-
grates at the expected molecular weight for a monomer
(V140 kDa), the puri¢ed enzyme from brain migrates at
V600 kDa using size-exclusion chromatography [30]. This
suggests that O-GlcNAcase is in a complex and in fact
O-GlcNAcase co-puri¢ed with several identi¢ed proteins in-
cluding the heat-shock proteins HSP110 and HSC70 [29]. One
intriguing observation is that O-GlcNAcase is processed by
caspase-3 to generate a 64 kDa C-terminal fragment [30].
Determining whether this proteolytic processing is separating
the O-GlcNAcase activity from regulatory domains or from
the putative acetyltransferase activity is an area of future in-
vestigation (see Fig. 1). The exact role that the O-GlcNAc
modi¢cation plays in and the importance of the cleavage of
O-GlcNAcase to apoptosis are currently areas of active re-
search in our group.
3. The hexosamine biosynthetic pathway, diabetes,
and O-GlcNAc (see Fig. 2)
The hexosamine biosynthetic pathway (HSP) generates the
sugar nucleotide UDP-GlcNAc, which is the donor for
O-GlcNAc addition to nucleocytoplasmic proteins (reviewed
in [33]). The ¢rst and rate-limiting step in this pathway is the
conversion of fructose-6-phosphate to glucosamine-6-phos-
Fig. 1. Enzymes of O-GlcNAc cycling. OGT adds O-GlcNAc to nucleocytoplasmic proteins and O-GlcNAcase removes the dynamic modi¢ca-
tion. Recent data suggest that OGT is targeted through various protein^protein interactions and splicing. O-GlcNAcase is a substrate for cas-
pase-3, an executioner protease in apoptosis.
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phate with the concomitant conversion of glutamine to gluta-
mate (see Fig. 2). This reaction is catalyzed by the enzyme
glutamine:fructose-6-phosphate amidotransferase (GFAT,
Fig. 2). Glucosamine-6-phosphate is then rapidly converted
through a series of steps to UDP-GlcNAc that can then be
used in glycosylation of lipids and proteins or be acted on by
other enzymes for the generation of other UDP-sugars. Ap-
proximately 4% of the glucose in the cell branches into this
pathway from glycolysis (see Fig. 2).
Marshall and colleagues were able to link increased £ux
through the HSP to insulin resistance in peripheral tissues
[34]. Insulin resistance is the hallmark of diabetes. Hypergly-
cemia, glucosamine treatment, free fatty acid elevation, as well
as overexpression of GFAT have all been shown to increase
£ux through the HSP and induce varying degrees of insulin
resistance (reviewed in [33]). Since O-GlcNAc modi¢cation is
dependent on £ux through the HSP (see Fig. 2), it has been
proposed as a possible mechanism for mediating insulin resis-
tance. In fact, elevated O-GlcNAc levels were found in dia-
betic rats, insulin resistance 3T3-L1 adipocytes, and athero-
sclerotic plaques of diabetic patients (reviewed in [33]). We
were able to establish a causal relationship between elevated
O-GlcNAc levels and insulin resistance in 3T3-L1 adipocytes
by pharmacological inhibition of the O-GlcNAcase [35]. Fur-
ther we were able to demonstrate that elevated levels of
O-GlcNAc inhibit proper insulin-dependent activation of
Akt. The ¢nding that the defect in insulin signaling was at
or above Akt is consistent with the work of others looking at
increased £ux through the HSP and insulin resistance [36].
Subsequently, transgenic mice overexpressing OGT in skeletal
muscle and fat were found to have lowered glucose disposal
rates [37]. Furthermore, endothelial nitric oxide synthase is
not properly activated when there are elevated O-GlcNAc
levels and glycogen synthesis appears to be impaired with
elevation of O-GlcNAc levels [38,39]. Since endothelial nitric
oxide synthase and glycogen synthase are both downstream of
Akt and appear to be O-GlcNAc-modi¢ed themselves, it ap-
pears that O-GlcNAc is either directly or indirectly modulat-
ing their activity. All of these data taken together suggest that
O-GlcNAc modi¢cation of nucleocytoplasmic proteins is serv-
ing as a negative feedback system for insulin signaling, but
elucidating the impact of O-GlcNAc at speci¢c sites on key
proteins remains to be investigated.
Another link to the diabetic state and elevated O-GlcNAc
levels is the ‘glucose toxicity’ observed in diabetes that is
believed to be responsible for many of the microvascular
and macrovascular complications. For example, mouse em-
bryonic ¢broblasts with impaired synthesis of UDP-GlcNAc
showed a marked increase in their ability to withstand apo-
ptotic stimuli [40]. Consistent with the above studies, in-
creased Akt activity (known to be anti-apoptotic) was seen
in these cells and lowered O-GlcNAc levels. Interestingly,
while O-GlcNAc levels were very responsive to the change
in UDP-GlcNAc levels, there were no detectable changes in
complex O- and N-linked glycosylation. Further, in retinal
neurons, increased £ux through the HSP was found to block
the protective e¡ect of insulin against apoptosis [41]. Also,
O-GlcNAcase is a substrate for the executioner caspase-3,
even though the e¡ect of proteolysis is not clear since cleavage
has no e¡ect on in vitro O-GlcNAcase activity [30]. Finally,
L-cells of the pancreas undergo apoptosis in response to strep-
tozotocin treatment. While the toxic e¡ects of this compound
are though to be mediated by its alkylating capability [42],
Kudlow and colleagues have shown that streptozotocin, a
GlcNAc mimetic, is a weak inhibitor of O-GlcNAcase [43].
All of these data together suggest that O-GlcNAc may be
playing a major role in diabetic complications and more
generally in apoptosis. The precise mechanism by which
O-GlcNAc modi¢cation is exerting its e¡ect however remains
to be determined.
4. O-GlcNAc and transcription
The C-terminal domain of RNA polymerase II is modi¢ed
by O-GlcNAc [44]. Recent work has demonstrated a recipro-
cal and inhibitory relationship between phosphorylation and
O-GlcNAc modi¢cation of this C-terminal domain [45]. Since
phosphorylation is required for elongation, the possibility ex-
ists that the O-GlcNAc-modi¢ed form of RNA polymerase II
is involved in the pre-initiation complex and may serve as a
checkpoint for premature elongation.
To date, more than 10 transcription factors have been
Fig. 2. Glucose metabolism in peripheral insulin-responsive tissues. Glucose can be metabolized through several pathways including the hexos-
amine biosynthetic pathway (from fruc-6-p to UDP-GlcNAc). The enzyme GFAT is shown since it is the rate-limiting step in UDP-GlcNAc
formation. UDP-GlcNAc serves as a high-energy sugar nucleotide donor for several processes including OGT-catalyzed modi¢cation of nucleo-
cytoplasmic proteins with O-GlcNAc.
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shown to be modi¢ed by O-GlcNAc [46]. In more than one
case the site of O-GlcNAc modi¢cation is the same as phos-
phorylation. For example, c-myc is O-GlcNAc-modi¢ed at
Thr58, a known site of phosphorylation and a mutational
hot spot in lymphomas [47]. Recent work suggests that
glycosylation of c-myc plays a role in protein stability and
subcellular localization of the transcription factor [48]. The
Sp-1 transcription factor is one of the most well studied
O-GlcNAc-modi¢ed proteins. Work has shown that O-Glc-
NAc modi¢cation of Sp-1 appears to modulate its transacti-
vation capability by a¡ecting Sp-1’s interaction with TAF110
[49]. Recent work looking at OGT interacting proteins has
identi¢ed OIP-106 and mSin3A, both of which may target
OGT to transcriptional complexes (reviewed in [4]). Interest-
ingly, mSin3A is part of a histone deacetylase complex and
OGT activity was shown to be required for maximal tran-
scriptional repression. Furthermore, increased O-GlcNAc
modi¢cation of p53 and NF-UL are associated with increased
transcriptional activity (reviewed in [6]). Thus, there is com-
pelling evidence that O-GlcNAc modi¢cation of the transcrip-
tional machinery is modulating activity. It remains to be elu-
cidated how O-GlcNAc is modulating activity at the
molecular level and how O-GlcNAc modi¢cation of the tran-
scription machinery is itself being regulated.
5. Conclusions and future directions
O-GlcNAc modi¢cation of nuclear and cytosolic proteins
was described in the 1980s. The majority of the work in the
1990s centered on identifying more modi¢ed proteins, the en-
zymes for its addition and subtraction, and the development
of tools to make the study of this modi¢cation less cumber-
some. Work at the turn of the century has begun to focus on
the function of this enigmatic modi¢cation. Thus, we believe
that O-GlcNAc, in an analogous manner to the history of
phosphorylation, is on the verge of an explosion in under-
standing. As more and more functional data concerning this
modi¢cation appear in the literature and as tools for its study
become available, more investigators are beginning to study
O-GlcNAc. We believe this has also been greatly facilitated by
the development of an O-GlcNAc-speci¢c antibody, the
cloned genes for OGT and O-GlcNAcase and a mass spec-
trometry-based technique for site-mapping that makes inves-
tigation more straightforward (reviewed in [6]). While some
functional studies have emerged, the precise roles of
O-GlcNAc in regulating signal transduction cascades, tran-
scription, translation, and the cell cycle remain to be eluci-
dated. There is also compelling evidence for O-GlcNAc being
involved in disease states such as diabetes, cancer, and age-
related neurological disorders but much work remains to be
performed to understand mechanisms. Our laboratory is using
a working model that O-GlcNAc modi¢cation of proteins is
acting as a nutrient sensor (reviewed in [50]). In this model,
cells are taking into account their energy levels to modulate
what proteins are produced in that cell. Also, modulation of
O-GlcNAc levels is impinging on extracellular-stimulated sig-
nal transduction events such that the cell is not acting as a
slave to the stimuli but instead is taking into account its
metabolic state and responding to the signal appropriately.
While this is an attractive model, it remains to be rigorously
tested. In conclusion, we believe that O-GlcNAc is now
emerging as an important regulatory modi¢cation.
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